

Laron Syndrome Market - A Global and Regional Analysis: Focus on Region and Country - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/LE14570EE94BEN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: LE14570EE94BEN

Abstracts

The global laron syndrome market is expanding steadily as awareness of primary IGF-1 deficiency and growth hormone insensitivity increases across leading pediatric endocrinology centers in the U.S., U.K., Europe, and select Asia-Pacific markets. Laron syndrome is a rare, autosomal recessive disorder caused by mutations in the growth hormone receptor (GHR) gene, resulting in normal or high serum growth hormone levels but markedly low circulating insulin-like growth factor-1 (IGF-1). Early genetic diagnosis, wider use of next-generation sequencing (ngs) panels for short-stature evaluation, and rare-disease policy support have together improved identification of eligible patients, which is directly supporting the growth of the laron syndrome market.

Therapeutic expansion in the laron syndrome market is driven almost entirely by recombinant human IGF-1 (mecasermin) therapy, which is the only disease-specific treatment option for these patients. In October 2024, Ipsen entered into an asset-purchase agreement to transfer INCRELEX (mecasermin injection) to Eton Pharmaceuticals. Eton will immediately commercialise INCRELEX in the U.S. upon closing and will assume full global responsibility following a six-month transition period during which Ipsen will continue distribution outside the U.S. This transition secures long-term product availability, clarifies commercial ownership, and strengthens supply continuity in the laron syndrome market. Alongside Eton, Giddi is also present in this space, and together Eton and Giddi are currently the only meaningful commercial players specifically active in the laron syndrome market. Growing clinician preference for earlier initiation of IGF-1 therapy to improve linear growth, craniofacial development, and metabolic parameters is expected to support sustained demand over the forecast period.

Even with these positive developments, the laron syndrome market continues to face several structural challenges. The ultra-low prevalence of the disease restricts patient pools, which makes large, controlled clinical trials difficult and prolongs evidence generation. Treatment remains costly due to the biologic nature of mecasermin, and reimbursement can be inconsistent in emerging markets. Long-term therapy also requires close monitoring for adverse events such as hypoglycemia, tonsillar/adenoidal hypertrophy, and intracranial hypertension, which increases the clinical management burden. These factors constrain uniform global penetration of therapy despite the clear clinical rationale for IGF-1 replacement.

At the same time, the laron syndrome market presents clear opportunities in improved genetic screening, newborn/early-childhood short-stature algorithms, and digital health-enabled growth tracking. As more countries include rare endocrine disorders in national rare-disease lists, access pathways are expected to improve. Patient registries and real-world evidence platforms can further support label refinement, dosing optimization, and long-term safety tracking for mecasermin. Over the forecast period, payer engagement, early diagnostic pathways, and cross-border rare-disease programs will be central to market expansion.

The competitive landscape of the laron syndrome market is currently concentrated. Eton Pharmaceuticals is positioned to become the primary commercial holder of INCRELEX globally following the Ipsen transition, managing U.S. commercialization immediately after closing and taking over ex-U.S. responsibilities after the six-month handover period. Ipsen's role becomes transitional and time-bound under the October 2024 agreement. Giddi remains the only other identified participant specifically referenced for laron syndrome-related activity. Unlike broader growth-hormone-deficiency markets where multiple multinationals operate, the laron syndrome market is narrow, therapy-specific, and largely driven by this single recombinant IGF-1 product and its supply continuity.

Market Segmentation:

Segmentation 1: by Region

North America

Europe

Asia-Pacific

Rest-of-the-World

The laron syndrome market is expected to maintain a stable but upward trajectory through 2035, supported by secured commercial transition of INCRELEX, growing genetic diagnosis of GH-receptor defects, and progressive inclusion of ultra-rare endocrine indications under national reimbursement and orphan-drug frameworks.

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days.

Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. GLOBAL LARON SYNDROME MARKET: INDUSTRY ANALYSIS

1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
 1.3.1 Impact Analysis
1.4 Patent Analysis
 1.4.1 Patent Filing Trend (by Country)
 1.4.2 Patent Filing Trend (by Year)
1.5 Regulatory Landscape
1.6 Ongoing Clinical Trials
1.7 Market Dynamics
 1.7.1 Overview
 1.7.2 Market Drivers
 1.7.3 Market Restraints
 1.7.4 Market Opportunities

2. GLOBAL LARON SYNDROME MARKET, BY REGION, \$MILLION, 2024-2035

2.1 North America
 2.1.1 Market Dynamics
 2.1.2 Market Sizing and Forecast
 2.1.3 North America Laron Syndrome Market, by Country
 2.1.3.1 U.S.
2.2 Europe
 2.2.1 Market Dynamics
 2.2.2 Market Sizing and Forecast
 2.2.3 Europe Laron Syndrome Market, by Country
 2.2.3.1 U.K.
 2.2.3.2 France

2.2.3.3 Germany

2.2.3.4 Italy

2.2.3.5 Spain

2.3 Asia-Pacific

2.3.1 Market Dynamics

2.3.2 Market Sizing and Forecast

2.3.3 Asia-Pacific Laron Syndrome Market, by Country

2.3.3.1 Japan

2.3.3.2 China

2.3.3.3 South Korea

2.3.3.4 Australia

2.3.3.5 India

2.4 Rest-of-the-World

2.4.1 Market Dynamics

2.4.2 Market Sizing and Forecast

3. GLOBAL LARON SYNDROME MARKET, COMPETITIVE LANDSCAPE AND COMPANY PROFILES

3.1 Competitive Landscape

3.1.1 Mergers and Acquisitions

3.1.2 Partnership, Alliances and Business Expansion

3.1.3 New Offerings

3.1.4 Regulatory Activities

3.1.5 Funding Activities

3.2 Company Profiles

3.2.1 Eton Pharmaceuticals, Inc.

3.2.1.1 Overview

3.2.1.2 Top Products / Product Portfolio

3.2.1.3 Top Competitors

3.2.1.4 Target Customers/End-Users

3.2.1.5 Key Personnel

3.2.1.6 Analyst View

3.2.2 Giddi

3.2.2.1 Overview

3.2.2.2 Top Products / Product Portfolio

3.2.2.3 Top Competitors

3.2.2.4 Target Customers/End-Users

3.2.2.5 Key Personnel

3.2.2.6 Analyst View

4. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Laron Syndrome Market (by Scenario), \$Million, 2024, 2030, and 2035

Figure: Global Laron Syndrome Market, 2024 and 2035

Figure: Global Laron Syndrome Market Key Trends, Impact Analysis

Figure: North America Laron Syndrome Market, \$Million, 2024-2035

Figure: Europe Laron Syndrome Market, \$Million, 2024-2035

Figure: Asia-Pacific Laron Syndrome Market, \$Million, 2024-2035

Figure: Rest-of-the-World Laron Syndrome Market, \$Million, 2024-2035

List Of Tables

LIST OF TABLES

Table: Market Snapshot

Table: Market Dynamics

Table: Global Laron Syndrome Market (by Region), \$Million, 2024-2035

I would like to order

Product name: Laron Syndrome Market - A Global and Regional Analysis: Focus on Region and Country
- Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/LE14570EE94BEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LE14570EE94BEN.html>